VRTHF - Veritas Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.25
-0.03 (-11.35%)
At close: 3:48PM EDT
Stock chart is not supported by your current browser
Previous Close0.28
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume43,592
Market Cap17.114M
Beta-1.46
PE Ratio (TTM)N/A
EPS (TTM)-0.09
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire11 hours ago

    Veritas Pharma Signs R&D and Medical Cannabis Supply Agreement with Colombian Producer Foliumed S.A.S.

    Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to announce that it has entered into a Memorandum of Understanding (“MOU”) with Colombian medical cannabis company Foliumed S.A.S. (“Foliumed”). Under the terms of the MOU, Veritas and Foliumed will jointly conduct scientific research, undertake product development activities, and commercialize select medical cannabis products with the help of Veritas’ research arm, Cannevert Therapeutics Ltd. (“CTL”).

  • GlobeNewswire19 days ago

    Veritas Pharma Provides Corporate Update on Q2 2018

    Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to provide a corporate update on its achievements, related scientific activities and growth strategies for the second quarter of fiscal 2018. Earlier this year, Veritas Pharma’s subsidiary Cannevert Therapeutics (“CTL”) signed an agreement with Puerto Rico’s Fundación de Investigación (“FDI”) Clinical Research to perform trials of its lead cannabis strain, CTL-X, to target pain.

  • GlobeNewswirelast month

    Veritas Pharma Has Retained Cannabis Branding Firm for Design of Label and Packaging

    Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) is pleased to announce with the dealer licence being granted which was previously announced on December 28, 2017, the Company has now engaged a branding firm in the development of label and package design in compliance of Health Canada regulations. Veritas is applying to amend Cannevert’s Dealer Licence such that the Company can package Cannevert products including CTL-X for sale to licensed producers in Canada and for the export market. CBD Strategy Group, a cannabis brand and marketing firm, has been retained to help develop brand strategy and guidelines around compliant packaging and labeling for both cannabis import and export.

  • GlobeNewswirelast month

    Veritas Pharma Provides Comment on Canadian Senate Recommendation for a One-Year Deferment Legalizing Cannabis

    Veritas Pharma Inc. (CSE:VRT) (VRTHF) (2VP.F), (“Veritas” or the “Company”) provides the following statement to the recommendation issued by Members of the Standing Senate Committee on Aboriginal Peoples calling for a one-year deferment to allow for further consultation with Indigenous groups on May 1, 2018. Members of the of the Standing Senate Committee on Aboriginal Peoples in the Canadian Senate are recommending the Liberal government hold back on legalizing cannabis for up to a year in order to address its potential for harmful effects in Indigenous communities. The committee, chaired by Liberal Saskatchewan Sen. Lillian Dyck, said in its report on Bill C-45 that the government simply did not consult enough with First Nations, Inuit and Métis communities before pushing ahead with its plan to legalize the drug.

  • GlobeNewswirelast month

    Veritas Pharma Establishes New Subsidiary in Puerto Rico, USA

    VANCOUVER, British Columbia, May 07, 2018-- Veritas Pharma Inc., is pleased to announce the establishment of new subsidiary Veritas Pharma Puerto Rico LLC in the US territory. With the management and regulatory ...

  • Should You Be Concerned About Veritas Pharma Inc’s (FRA:2VP) Shareholders?
    Simply Wall St.2 months ago

    Should You Be Concerned About Veritas Pharma Inc’s (FRA:2VP) Shareholders?

    In this article, I’m going to take a look at Veritas Pharma Inc’s (DB:2VP) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...

  • GlobeNewswire2 months ago

    Dr. Michael K. Pugsley Joins Veritas Pharma’s Advisory Board

    VANCOUVER, British Columbia, April 18, 2018-- Veritas Pharma Inc., is pleased to announce that Dr. Michael K. Pugsley PhD, FBPhS, DSP, a consultant in safety pharmacology, has joined its advisory board. ...

  • GlobeNewswire2 months ago

    Veritas Pharma Enters Into Share Purchase Agreement with 3 Carbon Extractions Inc.

    3 Carbon is in the business of designing cannabis extraction facilities and utilizing its own proprietary extraction methods. VANCOUVER, British Columbia, April 16, 2018-- Veritas Pharma Inc. is pleased ...

  • GlobeNewswire3 months ago

    Veritas Pharma Closes Private Placement

    VANCOUVER, British Columbia, March 29, 2018-- Veritas Pharma Inc. is pleased to announces the closing of a private placement of units. Under the terms of the Private Placement Offering, the Company will ...

  • GlobeNewswire3 months ago

    Veritas Pharma Completes the 100% Takeover of Cannevert Therapeutics

    VANCOUVER, British Columbia, March 21, 2018-- Veritas Pharma Inc. is pleased to announce the Company has completed the 100% takeover of its research arm, Cannevert Therapeutics Ltd... As previously announced ...

  • PR Newswire4 months ago

    BioCan Technologies Signs Memorandum of Understanding with Veritas Pharma

    CALGARY, Feb. 28, 2018 /CNW/ - BioCan Technologies Inc. ("BioCan" or the "Company") is pleased to announce that it has entered into a Memorandum of Understanding ("MoU") with Veritas Pharma Inc. ("Veritas") (CSE:VRT) (VRTHF) (Frankfurt: 2VP) to collaborate with Veritas on an exclusive basis to undertake further investigations of cannabis strains being developed by the research arm of Veritas, Cannevert Therapeutics Ltd. ("CTL"). The focus will be to optimize the genetics of their cannabis plants for scientific and clinical testing over the next two years.  Pursuant to the MoU, definitive agreements in respect of the transactions contemplated in the MoU are expected to be executed by the parties on or before July 31, 2018. BioCan's CEO, Trevor Peters, stated "We are pleased to be working with Veritas and their scientific teams to develop medically relevant cannabis strains and cannabinoid formulations with optimal therapeutic properties.

  • CNW Group4 months ago

    BioCan Technologies Signs Memorandum of Understanding with Veritas Pharma

    BioCan Technologies Signs Memorandum of Understanding with Veritas Pharma